Okomera
PrivateLast Round
Grant
Oct 21, 2024
Total Funding Raised
$12.8M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Okomera operates in Healthcare & Life Sciences and is based in Paris. Its latest recorded funding round was a Grant round in October 2024.
Okomera is a biotechnology research company that develops an automated organoid screening platform using microfluidics and AI to accelerate drug discovery and personalized cancer treatments.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Hardware + Subscription, Usage-Based SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Okomera Comparables
Compare Okomera with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Elephas Biosciences | 78% | |
| CN Bio | 77% | |
| Cellply | 76% |
For institutional investors. Book with your work email.
Okomera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 21, 2024 | ||||
| Seed | Dec 20, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Okomera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Berkeley SkyDeck | Seed |
| Resonance | Seed |
| Bpifrance | Grant |
| IQ-EQ | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 63% MoM.
- Jul 17, 2025
Grew 19% QoQ, from 27 to 32 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withOct 21, 2026
On Oct 21st '26, Okomera partners with Servier to use its machine, chips, and platform autonomously in experiments evaluating new oncology and immuno-oncology therapies, including treatments for pancreatic cancer and glioblastoma.
- hiresSep 16, 2026
Okomera appoints Marion Ghibaudo as Chief Technology Officer in France on Sep 16th '26; she leads the company's technology and innovation strategy, oversees industrial deployment, joins the Executive Committee, and reports to CEO Silvère Lucquin.
For institutional investors. Book with your work email.
Okomera Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Okomera's valuation, stock price, and market status.
Is Okomera a public or private company?
Okomera is a private company.
What is the current stock price of Okomera?
Okomera is a private company, so its shares have no public market price. Caplight tracks Okomera's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Okomera worth (valuation)?
Valuation information for Okomera is not publicly available.
Can I buy Okomera stock?
Okomera shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Okomera's last funding round?
Okomera's most recent funding round was Grant on October 21, 2024.
Who are the main investors in Okomera?
Key investors in Okomera include Resonance.
Will Okomera IPO soon?
No public IPO plans have been announced for Okomera.
How can I track Okomera secondary market activity?
Caplight tracks bids, offers, and trades in Okomera's shares on secondary markets.